Premium
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease
Author(s) -
BaraJimenez William,
Dimitrova Tzvetelina,
Sherzai Abdulah,
Favit Antonella,
Mouradian M.M.,
Chase Thomas N.
Publication year - 2004
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20124
Subject(s) - levodopa , dyskinesia , reuptake , parkinson's disease , reuptake inhibitor , dopamine , medicine , placebo , monoamine neurotransmitter , psychology , pharmacology , disease , antidepressant , serotonin , receptor , alternative medicine , pathology , hippocampus
Dopamine reuptake blockers, by enhancing and stabilizing intrasynaptic transmitter levels, could help palliate motor dysfunction in Parkinson's disease. This randomized, double‐blind, placebo‐controlled study compared the acute effects of the monoamine uptake inhibitor NS 2330 to those of placebo in 9 relatively advanced parkinsonian patients. At the dose administered, no change in parkinsonian scores was found when NS 2330 was given alone or with levodopa. Moreover, NS 2330 coadministration did not appear to alter dyskinesia severity or the duration of the antiparkinsonian response to levodopa. The drug was well tolerated. Under the conditions of this study, the present results failed to support the usefulness of dopamine reuptake inhibition in the treatment of advanced Parkinson's disease. © 2004 Movement Disorder Society